アブストラクト
| Title | 肝細胞癌における薬物療法の進歩と今後の展開 |
|---|---|
| Subtitle | 今月のテーマ (総論) : 肝細胞癌における薬物治療の進歩 |
| Authors | 工藤正俊1) |
| Authors (kana) | |
| Organization | 1)近畿大学消化器内科 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 118 |
| Number | 5 |
| Page | 379-399 |
| Year/Month | 2021 / 5 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨:切除不能肝細胞癌に対する2009年のソラフェニブの承認以来, 一次治療薬としてレンバチニブ, アテゾリズマブとベバシズマブの併用療法が, そして二次治療薬としてレゴラフェニブ, カボザンチニブ, ラムシルマブの計6レジメンが承認され, 現在臨床で使用可能となっている. これらの全身薬物療法は進行肝癌のみならずintermediate stage肝癌の治療パラダイムも大きく変えつつあり, さらには現在進行中の第III相試験である, 免疫療法の切除・ablation後のアジュバントやTACE併用において良好な結果が得られれば, 肝癌患者の予後はドラスティックに向上するものと期待される. |
| Practice | 臨床医学：内科系 |
| Keywords | 肝細胞癌, 薬物療法, 分子標的薬, 免疫チェックポイント阻害薬, 免疫微小環境 |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Kudo M: Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 9;640-662:2020
- 2) Hiraoka A, Kumada T, Fukunishi S, et al: Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer 9;73-83:2020
- 3) Bouattour M, Mehta N, He AR, et al: Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer 8;341-358:2019
- 4) Rimassa L, Pressiani T, Merle P: Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer 8;427-446:2019
- 5) Alsina A, Kudo M, Vogel A, et al: Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer 9;93-104:2020
残りの95件を表示する
- 6) Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359;378-390:2008
- 7) Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10;25-34:2009
- 8) Tohyama O, Matsui J, Kodama K, et al: Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747:2014
- 9) French DM, Lin BC, Wang M, et al: Targeting FGFR4 inhibits hepatocellular carcinoma in pre-clinical mouse models. PLoS One 7;e36713:2012
- 10) Ikeda K, Kudo M, Kawazoe S, et al: Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52;512-519:2017
- 11) Kudo M, Finn RS, Qin S, et al: A Randomised Phase 3 trial of lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. Lancet 391;1163-1173:2018
- 12) Matsuki R, Kawai K, Suzuki Y, et. al: Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma. Liver Cancer 9;358-360:2020
- 13) Cheon J, Chon HJ, Bang Y, et al: Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. Liver Cancer 9;613-624:2020
- 14) Wilhelm SM, Dumas J, Adnane L, et al: Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129;245-255:2011
- 15) Bruix J, Qin S, Merle P, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389;56-66:2017
- 16) Finn RS, Merle P, Granito A, et al: Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol 69;353-358:2018
- 17) Trojan J: Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs 80;1203-1210:2020
- 18) Abou-Alfa GK, Meyer T, Cheng AL, et al: Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379;54-63:2018
- 19) Kudo M, Tsuchiya K, Kato N, et al: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol 56;181-190:2021
- 20) Zhu AX, Park JO, Ryoo BY, et al: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-biind, multicentre, phase 3 trial. Lancet Oncol 16;859-870:2015
- 21) Zhu AX, Kang YK, Yen CJ, et al: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20;282-296:2019
- 22) Kudo M, Hatano E, Ohkawa S, et al: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol 52;494-503:2017
- 23) Yen CJ, Kudo M, Lim HY, et al: Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein:Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer 9;440-454:2020
- 24) Kudo M: Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma. Liver Cancer 9;232-244:2020
- 25) Kudo M, Galle PR, Llovet JM, et al: Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int 40;2008-2020:2020
- 26) Kudo M. Galle PR, Brandi G, et al: Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep 3;100215:2021
- 27) Sensui M, Ogasawara S, Ooka Y, et al: Survival among patients with advanced hepatocellular carcinoma in the pre-TKI versus TKI eras. EASL, April 10-14, Vienna. Abstr #FRI-501:2019
- 28) Raoul JL, Adhoute X, Penaranda G. et al: Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer 8;457-467:2019
- 29) Tovoli F, Ielasi L, Casadei-Gardini A, et al: Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol 71;1175-1183:2019
- 30) Ogasawara S, Ooka Y, Itokawa N, et al: Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs 38;172-180:2020
- 31) Hiraoka A, Kumada T, Atsukawa M, et al: Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology 97;277-285:2019
- 32) Wang W, Tsuchiya K, Kurosaki M, et al: Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensitv and Post-Regorafenib Therapies in Real World Practice. Cancers 11;1517:2019
- 33) Ogasawara S, Chiba T, Ooka Y, et al: Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs 36;332-339:2018
- 34) Kuzuya T, Ishigami M, Ito T, et al: Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol Res 49;1054-1065:2019
- 35) Uchikawa S, Kawaoka T, Aikata H, et al: Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 48;814-820:2018
- 36) Terashima T, Yamashita T, Sunagozaka H, et al: Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. Hepatol Res 48;956-966:2018
- 37) Yukimoto A, Hirooka M, Hiraoka A, et al: Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma. Jpn J Clin Oncol 49;42-47:2019
- 38) Takada H, Kurosaki M, Tsuchiya K, et al: Base-line and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. Cancers 11;1256:2019
- 39) Kirstein MM, Scheiner B, Marwede T, et al: Sequential systemic treatment in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 52;205-212:2020
- 40) Kobayashi K, Ogasawara S, Iwanaga T, et al: Effects of molecular target agent therapy in advanced hepatocellular carcinoma: a multicenter, retrospective study. ILCA,114:2020
- 41) Marrero JA, Kulik LM, Sirlin CB, et al: Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68;723-750:2018
- 42) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69;182-236:2018
- 43) Kokudo N, Takemura N, Hasegawa K, et al: Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 49;1109-1113:2019
- 44) Kudo M, Izumi N, Kokudo N, et al: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29;339-364:2011
- 45) Kudo M, Matsui O, Izumi N, et al: Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update. Oncology 87(suppl 1);22-31:2014
- 46) Raoul JL. Gilabert M, Piana G: How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 3;119-124:2014
- 47) Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc 117;381-403:2018
- 48) Cheng AL, Amarapurkar D, Chao Y, et al: Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 34;174-183:2014
- 49) Ogasawara S, Chiba T, Ooka Y, et al: Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. Oncology 87;330-341:2014
- 50) Arizumi T, Ueshima K, Chishina H, et al: Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. Oncology 87(suppl 1);32-36:2014
- 51) Peck-Radosavljevic M, Kudo M, Raoul J, et al: Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. J Clin Oncol 36(suppl);abstr 4018:2018
- 52) Peck-Radosavljevic M, Lee HC, Kudo M, et al: Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were either ineiigible or eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis. EASL, April 10-14, Vienna, Abstr #FRI-494:2019
- 53) Kudo M, Han KH, Ye SL, et al: A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 9;245-260:2020
- 54) 日本肝臓学会: 肝癌診療マニュアル, 第4版, 医学書院,東京, 2020
- 55) Kudo M, Kawamura Y, Hasegawa K, et al: Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statement and Recommendations 2021 Update. Liver Cancer (in press)
- 56) Kudo M, Ueshima K, Chan S, et al: Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers 11;1084:2019
- 57) Kudo M: A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 8;299-311:2019
- 58) Kawamura Y, Kobayashi M, Shindoh J, et al: 18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib. Liver Cancer 9;84-92:2020
- 59) Kawamura Y, Kobayashi M, Shindoh J, et al: Pre-treatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer 9;275-292:2020
- 60) Kawamura Y, Kobayashi M, Shindoh J, et al: Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. Liver Cancer 9;756-770:2020
- 61) Llovet JM, Villanueva A, Marrero JA, et al: Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 73(suppl 1);158-191:2021
- 62) Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307;58-62:2005
- 63) Kudo M, Ueshima K, Ikeda M, et al: Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 69;1492-1501:2020
- 64) Lencioni R, Llovet JM, Han G. et al: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 64;1090-1098:2016
- 65) Meyer T, Fox R, Ma YT, et al: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2;565-575:2017
- 66) Kudo M, Imanaka K, Chida N, et al: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47;2117-2127:2011
- 67) Kudo M, Han G, Finn RS, et al: Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology 60;1697-1707:2014
- 68) Kudo M, Cheng AL, Park JW, et al: Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 3;37-46:2018
- 69) Kudo M, Ueshima K, Ikeda M, et al: TACTICS: Final Overall Survival Data from a Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy In Combination with Sorafenib as compared with TACE Alone in Patients with Hepatocellular Carcinoma. ASCO-GI, 2021
- 70) Llovet JM, Montal R, Villanueva A: Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol 70;1262-1277:2019
- 71) Terashima T, Yamashita T, Takata N, et al: Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatol Res 46;650-656:2016
- 72) El-Khoueiry AB, Sangro B, Yau T, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389;2492-2502:2017
- 73) Yau T, Park JW, Finn RS, et al: CheckMate 459: A randomized, multi-center phase III study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. Ann Oncol 30(suppl 5);v874-v875:2019
- 74) Zhu AX, Finn RS, Edeline J, et al: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19;940-952:2018
- 75) Finn RS, Ryoo BY, Merle P, et al:Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 38;193-202:2020
- 76) Kudo M: Gd-EOB-DTPA-MRI could predict WNT/β-catenin mutation and resistance to immune checkpoint inhibitor therapy in hepatocellular carcinoma. Liver Cancer 9;479-490:2020
- 77) Sia D, Jiao Y, Martinez-Quetglas I, et al: Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 153;812-826:2017
- 78) Xue G, Romano E, Massi D, et al: Wnt/beta-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. Cancer Treat Rev 49;1-12:2016
- 79) Kudo M: Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies. Liver Cancer 8;413-426:2019
- 80) Kudo M: Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. Liver Cancer 8;1-11:2019
- 81) Kudo M: A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer 9;119-137:2020
- 82) Pinyol R, Sia D, Llovet JM: Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC. Clin Cancer Res 25;2021-2023:2019
- 83) Teng MW, Ngiow SF, Ribas A, et al: Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res 75;2139-2145:2015
- 84) Chen DS, Mellman I: Oncology meets immunology: the cancer-immunity cycle. Immunity 39;1-10:2013
- 85) Kudo M: Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers 12;1089:2020
- 86) Voron T, Marcheteau E, Pernot S, et al: Control of the immune response by pro-angiogenic factors. Front Oncol 4;70:2014
- 87) Harding JJ, Nandakumar S, Armenia J, et al: Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res 25;2116-2126:2019
- 88) Yamauchi M, Ono A, Ishikawa A, et al: Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanccd Hepatocellular Carcinoma. Clin Transl Gastroenterol 11;e00179:2020
- 89) Finn RS, Qin S, Ikeda M, et al: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382;1894-1905:2020
- 90) Finn RS, Ikeda M, Zhu AX, et al: Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatoccllular carcinoma. J Clin Oncol 38;2960-2970:2020
- 91) Kudo M, Ikeda K, Motomura K, et al: A Phase 1b Study of Lenvatinib Plus Nivolumab in Patients With Unresectable Hepatocellular Carcinoma. ASCO-GI. January 23-25, San Francisco, Abstr #513:2020
- 92) Lee MS, Ryoo BY, Hsu CH, et al: Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre. phase 1b study. Lancet Oncol 21;808-820:2020
- 93) Siegel AB, Cohen EI, Ocean A, et al: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26;2992-2998:2008
- 94) Cheng AL, Hsu C, Chan SL, et al: Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 72;307-319:2020
- 95) Lin YY, Tan CT, Chen CW, et al: Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Semin Liver Dis 38;379-388:2018
- 96) Osa A, Uenami T, Koyama S, et al: Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3;e59125:2018
- 97) Aoki T, Kudo M, Ueshima K, et al: Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. Cancers 12;3048:2020
- 98) Finn RS, Qin S, Ikeda M, et al: IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma. ASCO-GI (Virtual), January 15-17,2020
- 99) Yau T, Kang YK, Kim TY, et al: Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 6;e204564:2020
- 100) Kelley RK, Sangro B, Harris WP, et al: Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). J Clin Oncol 38;4508:2020
